SHP2 inhibition reduces somatotroph tumor growth in a pre-clinical model
F Barberá, Florencia Picech, Laura Anahí Cecenarro, Gilda Florencia Mezger et autres
BACKGROUND: In somatotroph tumors, over 50% of patients do not respond satisfactorily to the octreotide (OCT) treatment. Stimulation of SSTR2 with OCT triggers anti-proliferative signaling pathways mediated by the phosphatase SHP2. This phosphatase can exercise its functions through the STAT3, with the …
ar, us (code pays fourni par la source)
2 citations
Neuro-Oncology